Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy-Reference-Cited by-同舟云学术

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy

Published:2022-09 Issue: Volume:172 Page:332-339
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Corti Chiara^ORCID,Conforti Fabio,Pala Laura,Catania Chiara,Cocorocchio Emilia,Ferrucci Pier Francesco^ORCID,Curigliano Giuseppe^ORCID,Queirolo Paola,de Pas Tommaso^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. AACR project GENIE: powering precision medicine through an international consortium;Consortium APG;Cancer Discov,2017

2. Gastrointestinal stromal tumours: origin and molecular oncology;Corless;Nat Rev Cancer,2011

3. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation;Antonescu;Clin Cancer Res,2005

4. Secondary KIT mutations: the GIST of drug resistance and sensitivity;Napolitano;Br J Cancer,2019

5. Primary mucosal melanomas: a comprehensive review;Mihajlovic;Int J Clin Exp Pathol,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes;Frontiers in Immunology;2024-07-30

2. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?;The Cancer Journal;2024-03

3. Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas;Cancers;2023-12-29

4. The compassionate use of drugs in palliative care for symptom control and ethical justifications for its use: A scoping review;Ethics, Medicine and Public Health;2023-12

5. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022;Orphanet Journal of Rare Diseases;2023-11-28